| Literature DB >> 35519937 |
Bin-Bin Gu1, Fu-Rong Jiao1, Wei Wu1, Lei Liu1, Wei-Hua Jiao1, Fan Sun1, Shu-Ping Wang1, Fan Yang1, Hou-Wen Lin1.
Abstract
A novel ochratoxin-ergosteroid heterodimer, ochrasperfloroid (1), together with a known mycotoxin, ochratoxin A (2), were isolated from the sponge-derived fungus Aspergillus flocculosus 16D-1. The structure of 1 was determined on the basis of 1D/2D NMR, HRESIMS/MS, and LC-UV/MS analysis of its alkaline hydrolyzates, quantum-chemical 13C NMR calculation, and comparison with literature data. Of note, the ergosteroid embedded in 1 is also a new structure. Ochrasperfloroid (1) showed potent inhibitory activity towards IL-6 production in lipopolysaccharide (LPS)-induced THP-1 cell line, with an IC50 value of 2.02 μM, and NO production in LPS-activated RAW264.7 macrophages, with an IC50 value of 1.11 μM. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35519937 PMCID: PMC9061062 DOI: 10.1039/c8ra10539a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1Structures of 1 and 2.
1H (600 MHz) and 13C (150 MHz) NMR data of 1 in DMSO-d6, coupling constants in Hz (in brackets)
| Position |
|
| Position |
|
|
|---|---|---|---|---|---|
| 1 | 23.1, CH2 | α2.18, brd (14.3) | 26 | 15.6, CH3 | 0.70, d (6.8) |
| β1.89, td (14.3, 3.2) | 27 | 21.8, CH3 | 0.86, d (6.9) | ||
| 2 | 29.2, CH2 | α1.33 | 28 | 10.0, CH3 | 0.67, d (6.9) |
| β1.50 | 12-OH | 6.28, d (4.3) | |||
| 3 | 64.4, CH | 4.01 | 1′ | 168.3, C | |
| 4 | 31.8, CH2 | α1.32, brd (14.1) | 3′ | 75.4, CH | 4.85, m |
| β1.97, brd (14.1) | 4′ | 31.6, CH2 | 3.23 | ||
| 5 | 75.1, C | 2.91, dd (17.3, 11.7) | |||
| 6 | 78.5, CH | 5.62, s | 5′ | 121.5, C | |
| 7 | 193.7, C | 6′ | 136.0, CH | 8.06, s | |
| 8 | 145.5, C | 7′ | 120.1, C | ||
| 9 | 146.8, C | 8′ | 158.3, C | ||
| 10 | 44.2, C | 9′ | 111.3, C | ||
| 11 | 202.5, C | 10′ | 141.7, C | ||
| 12 | 82.1, CH | 3.47, d (4.3) | 11′ | 163.0, C | |
| 13 | 54.7, C | 12′-NH | 8.65, d (8.0) | ||
| 14 | 80.7, C | 13′ | 53.7, CH | 5.06, td (8.0, 5.0) | |
| 15 | 49.6, CH2 | 2.27, m | 14′ | 36.8, CH2 | 3.21 |
| 16 | 85.0, CH | 4.75, td (7.4, 2.5) | 3.36, dd (14.0, 5.0) | ||
| 17 | 58.7, CH | 2.32, t (7.4) | 15′ | 136.6, C | |
| 18 | 15.14, CH3 | 0.93, s | 16′ | 129.4, CH | 7.36, d (7.4) |
| 19 | 22.7, CH3 | 1.48, s | 17′ | 128.3, CH | 7.29, t (7.4) |
| 20 | 38.7, CH | 2.64, m | 18′ | 126.7, CH | 7.22, t (7.4) |
| 21 | 15.08, CH3 | 1.04, d (6.9) | 19′ | 128.3, CH | 7.29, t (7.4) |
| 22 | 81.6, CH | 4.00 | 20′ | 129.4, CH | 7.36, d (7.4) |
| 23 | 72.7, CH | 3.14, dd (9.1, 1.7) | 21′ | 20.1, CH3 | 1.47, d (6.3) |
| 24 | 40.3, CH | 1.56, m | 22′ | 170.2, C | |
| 25 | 25.5, CH | 2.10, m | 8′-OH | 12.61, s |
Overlapped with other signals.
Fig. 2Key COSY and HMBC correlations of 1.
Fig. 3HRESIMS/MS fragment ions (m/z) of 1. (a) Positive ion mode; (b) negative ion mode.
Fig. 4LC-UV/MS chromatograms. (a) Standard compound 1; (b) standard compound 2; (c) EtOAc extract of the hydrolysis product of pure compound 1 in sodium hydroxide (2 M). The MS spectra of the peaks with green frame are shown in the insets (negative ionization mode).
Fig. 5(a) Key ROESY correlations of 1 (A1, rings A/B; B1, rings D/E). (b) The expected ROESY correlations on the structures of C-5 epimer of 1 (A2, rings A/B) and C-14 epimer of 1 (B2, rings D/E). (c) Relative configuration of the C-22 alkanol side chain of 1 determined by one- and two-dimensional NMR analysis (solid arrows, selected ROE correlations; dashed arrows, coupling constants).
Fig. 6Regression analysis of experimental 13C NMR chemical shifts of moiety B in 1versus calculated 13C NMR chemical shifts of model I at b3lyp/6-311 + g(2d,p) PCM (DMSO) level; linear fitting is shown as a line. The structure of model I is shown in the inset.
Determination of mitigation of IL-6 production in induced THP-1 cells and NO production in activated RAW264.7 cells [given as IC50 (μM)]
| Compound | IL-6 | NO |
|---|---|---|
| 1 | 2.02 | 1.11 |
| 2 | >25 | >100 |
| Corylifol A | 0.88 | |
| Diphenyleneiodonium chloride | 0.06 |
Positive control for inhibition of IL-6 production.
Positive control for inhibition of NO production.